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Abstract
Objectives A refractory chronic migraine (RCM) accompanied by medication-overuse headache (MOH) is an extremely dis-
abling disease. Evidence suggests that in selected patients, chronic opioids may be a valuable therapeutic option for RCM. The
aim of the present study was to evaluate the effectiveness and safety of prophylaxis with low-dose methadone (LDM) in patients
affected by RCM with continuous headache and MOH.
Methods A prospective cohort study was performed between May 2012 and November 2015 at the Headache Center and
Toxicology Unit of the Careggi University Hospital. Eligible patients were treated with prophylactic LDM and followed up
for 12 months. Headache exacerbations, pain intensity, use of rescue medications, and occurrence of adverse drug reactions
(ADRs) were recorded.
Results Thirty patients (24 females, median age 48 years) were enrolled. Nineteen (63%) patients dropped out, mainly because of
early ADRs (n = 10), including nausea, vomiting, and constipation. At last available follow-up, LDM was associated with a
significant decrease in the number of headache attacks/month (from a median of 45 (interquartile range 30–150) to 16 (5–30),
p < 0.001), in pain intensity (from 8.5 (8–9) to 5 (3–6), p < 0.001), and in the number of rescue medications consumed per month
(from 95 (34–240) to 15 (3–28), p < 0.001). No misuse or diversion cases were observed.
Conclusion LDM could represent a valuable and effective option in selected patients affected by RCMwith continuous headache
and MOH, although the frequency of early ADRs poses major safety concerns. Randomized controlled trials are needed to
confirm the efficacy and safety of LDM prophylaxis.
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Introduction
Chronic migraine is increasingly disabling, making patients
with continuous headache the most disabled in the spectrum
of chronic migraineurs [1]. Chronic migraine affects at least
1% of the general population [2], and refractoriness to
treatments (RCM, refractory chronic migraine) [3] and
medication-overuse headache (MOH) [1] often aggravate this
condition. Even if there is no conclusive consensus on its
definition, refractoriness is a clinically relevant phenomenon
that refers to the failure of at least 2 of 4 prophylactic treat-
ments of different pharmacological classes [4]. As the prophy-
laxis fails, the risk for the patient to experience medication
overuse and, consequently, undergo MOH significantly in-
creases. Importantly, even if the majority of patients who
discontinued medication overuse substantially improve
[5–8], drug discontinuation is not always sufficient for the
reduction of headache attack frequency or intensity. In a con-
siderable portion of patients, chronic pain and exposure to
adverse drug reactions (ADRs), due to the intense consump-
tion of nonsteroidal anti-inflammatory drugs (NSAIDs), anal-
gesics, and/or triptans, lead to a vicious cycle that progressive-
ly deteriorates patients’ health and quality of life.
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Despite some drawbacks, including the potential for misuse
and diversion and the risk of cognitive impairment, continuous
opioid therapy represents a reasonable prophylactic option for
patients affected by RCM with continuous headache and MOH
[9]. In 2009, the American Pain Society proposed chronic head-
aches as one of the four chronic pain conditions where continu-
ous opioid therapy might be taken into consideration [10].
According to the data from longitudinal studies and a long-
standing experience with refractory patients and opioid sched-
ules, guidelines for the selection of patients eligible to continuous
opioid therapy have been proposed [11].
Little evidence is available regarding the preferred opioid
schedules for RCM with continuous headache and MOH.
Methadone, because of the peculiar pharmacological profile of
its racemic mixture of (R)- and (S)-isomers, seems to be a better
candidate compared with other opioids, in particular for its dura-
tion of action (long-acting opioid), with an analgesic effect that
persists for 4–6 h [12]. Methadone has a mean bioavailability of
about 80%, which is much higher than for the other opioid; in
addition, it also has a long terminal half-life ranging from 7 to
65 h compared with other clinically used opioids [13]. Although
metabolism and disposition are highly variable among subjects,
theappropriatedosage tailoringallows tomaximallybenefit of the
pharmacokinetic profile of methadone for patients’ treatment. Its
primary analgesic effect is mediated by the agonism of the sole
(R)-methadone onμ-opioid receptors. However, both isomers act
as antagonists of the N-methyl-D-aspartate (NMDA) glutamate
receptor [14], likely contributing to a reduced opioid tolerance
[15] especially at low doses [16, 17]. The favorable profile of
methadone in termsof reduced tolerance incomparisonwithother
opioids is another key point for the administration of methadone
for chronicpain therapy.Somepreclinical evidence suggests it has
an optimal profile regarding the ability to induce opioid receptor
internalization that may explain this clinical phenomenon [18].
Despite its proven efficacy, methadone has a relevant potential
for drug interactions and may be associated with serious ADRs,
among which is the dose-independent prolongation of the QT
interval [19] leading to rare but potentially fatal arrhythmias.
Thus, the clinical use of methadone requires trained physicians, a
careful education of patients, and a strict monitoring;
nevertheless, the use of low dosages is recommended.
In this clinical context, the aim of the present study was to
evaluate the effectiveness and safety, at 12 months of treat-
ment, of low doses of methadone (LDM) in patients affected
by RCM with continuous headache and MOH.
Methods
Study design and setting
A prospective cohort study was performed at the Headache
Center and Toxicology Unit of the Careggi University
Hospital. The study was approved by the Ethics Committee
on Clinical Research (Comitato Etico Regione Toscana,
Sezione Area Vasta Centro; approval number 6078) and reg-
istered in the Italian Registry for Observational Studies held
by the Italian Medicines Agency (AIFA). The study was per-
formed following all the guidelines for observational studies
with human subjects required by the institution with which all
the authors are affiliated. A written informed consent for re-
search was obtained from all participants.
Study population
Between May 2012 and November 2015, patients aged ≥
30 years were screened at the Headache Center of Careggi
University Hospital and, if diagnosed with RCM with contin-
uous headache andMOH, were informed about the possibility
of receiving prophylactic LDM. Only patients with refractory
headache or with contraindications to the use of evidence-
based interventions were eligible [11]. Patients were consid-
ered not eligible in case of contraindications to opioid treat-
ment, including past addictive disease or serious mental ill-
nesses [11]. Before starting the LDM, patients underwent a
psychiatric evaluation in order to exclude lifetime diagnosis of
schizophrenia or other psychiatric syndromes according to the
Diagnostic and Statistical Manual of Mental Disorders (DSM)
[5] and clinical assessment, including electrocardiography
(ECG) and urine drug screening. According to standard clin-
ical practice, patients that resulted eligible after clinical
screening were informed about possible drug-drug interac-
tions related to methadone treatment. In order to avoid possi-
ble interactions and optimize treatment, an informative letter
was sent to the general practitioner of each patient.
According to standard practice, patients should have their
headache diary reporting data about their chronic migraine in
the previous 3 months. Information reported in this diary in-
cluded the number of rescue medications (including non-
opioid analgesics, NSAIDs, and triptans) consumed per
month, the number of days with headache per month, the
number of headache exacerbations deserving pain relievers
per month, and their intensity assessed every day by the visual
analogue scale (VAS).
Data from the headache diaries were used as baseline
values for study assessments. After signature of the informed
consent, eligible patients were transferred to the Toxicology
Unit, where all the clinical procedures and study follow-up
visits were performed.
The baseline visit was conducted at T0 (i.e., day of LDM
start). All treated patients were prescribed with standard pro-
phylaxis (i.e., enriched fiber diet, physical activity, lactulose if
needed) to prevent methadone-induced constipation. LDM
started from 2 mg per day and was increased or administered
in multiple daily doses according to clinical evaluation, since
no dosing strategy for initiation of therapy and later uptitration
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have been validated. In our patients, maximal dose adminis-
tered was 30 mg per day at T0. and 40 mg per day at T4.
Follow-up visits were planned at T1 (30 days following T0),
T2 (3 months after T0), T3 (6 months after T0), and T4
(12 months after T0). The variability in the time interval be-
tween subsequent visits was due to the increased need of
follow-up in the initial phases of the treatment, when titration
of the methadone doses can still be critical.
Outcome evaluation
The primary outcome was headache exacerbations. The pri-
mary endpoint was the number of headache exacerbations per
month requiring a pain reliever.
The secondary outcomes were the pain intensity and the
need of rescuemedications. The secondary endpoints were the
changes in pain intensity, measured using the VAS, and the
number of rescue medications consumed per month.
Safety outcomes included all ADRs occurred during LDM
treatment. Namely, safety endpoints were the number and the
grade of ADRs recorded. To this aim, ECG recordings were
performed at T0, T1, and T4 in order to detect QTc changes
possibly due to administration of LDM.
Statistical analysis
Data were reported as mean value ± standard deviation of the
mean (SD) or as median value and related interquartile range
(IQR), according to data distribution.
Effectiveness and safety endpoints were evaluated at T1,
T2, T3, and T4 and compared with T0 using the Wilcoxon test
for paired data. Furthermore, effectiveness and safety end-
points at T0 were compared with those obtained at last avail-
able follow-up, i.e., T1, T2, T3, or T4, according to patients’
data availability. Statistical significance was considered for p
value < 0.05. An analysis was conducted using the software
STATA version 14.
Results
Thirty patients were considered eligible for LDM and were
further enrolled in the study. Of them, 24 were females
(80.0%), with a median age of 48 years (41.2–54.2).
Demographic and clinical characteristics of the enrolled co-
hort are detailed in Table 1.
Focusing on the previous pharmacological treatment of
headache, 93.3% of patients overused NSAIDs (n = 28), 17
(56.7%) overused triptans, and the other 17 overused opioids.
Acetaminophen was overused by 11 patients (36.7%).
Notably, patients assumed more than one drug class to treat
headache exacerbations. Concerning failed prophylaxes, tri-
cyclic antidepressants, calcium-channel blockers, and
antiepileptics were reported as previous treatment by 73% of
patients, while beta-blockers and onabotulinum toxin A by
67% of patients. Importantly, 40% of patients are reported to
have been treated with at least four of the abovementioned
drug classes, while 60% of patients have tried them all.
As for comorbidities, most patients suffered from anxiety
(66.7%), whereas arterial hypertension and other pain condi-
tions were reported in 30.0 and 23.3% of patients,
respectively.
LDM was initiated during in-hospital stay (2–3 days) in 28
patients, while 2 patients started LDM in a day-hospital set-
ting. An initial mean dose of methadone was 12 ± 4 mg (IQR
8–17 mg).
The demographic and clinical characteristics of patients are
detailed in Table 2. Nineteen (63.3%) patients discontinued
LDM. Specifically, five (16.7%) withdrew because of ineffec-
tiveness, after a median time of 4.6 months (IQR 3.5–5.5).
Although LDM treatment was effective, fourteen patients
withdrew for other reasons. Among them, ten (33.3%) with-
drew because of ADR; it is worth noting that all were female.
Other three patients (10.0%) dropped out because of poor
treatment confidence, while one patient moved to another
country and was therefore lost to follow-up. Eleven patients
(36.7%) were still on LDM treatment at the end of our study.
The persistence on LDM treatment, distinguishing patients
that developed an ADR (n = 10) from the others (n = 20), is
shown in Fig. 1 (solid and dashed lines, respectively).
The effectiveness of LDM in terms of headache exacerba-
tions, pain reduction, and use of rescue medications is de-
scribed in Fig. 2. At time of start of LDM treatment (T0), the
mean number of headache exacerbations per month requiring
a pain reliever in the 30 enrolled patients was of 68.5 ± 60.4
Table 1 Demographic and clinical data of patients treated with low-
dose methadone (LDM)
Median (IQR) or n (%)
Demographic data









Arterial hypertension 9 (30.0)
Other pain conditions 7 (23.3)
*Some patients overused more than one drug
IQR interquartile range, NSAIDs nonsteroidal anti-inflammatory drugs
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(median 45, IQR 30–90) (Fig. 2A). At T1, the mean number of
attacks requiring a pain reliever in the 25 observed patients
significantly decreased to 15.9 ± 12.4 (median 9, IQR 5–30;
p < 0.001). This significant reduction in the monthly number
of headache exacerbations was confirmed also at the other
time points of follow-up. Specifically, at T2, among the 19
patients for whom follow-up data were available, the mean
number of attacks was of 24.8 ± 26.0 (median 30, IQR 7–30;
p = 0.003). At T3, among the 15 observed patients, the mean
of attacks was of 24.9 ± 29.2 (median 26, IQR 4–30; p =
0.002), and at T4, the mean number in the 11 observed patients
was of 17.1 ± 11.4 (median 16, IQR 5–30; p = 0.003). At time
of the last follow-up available for each patient (ranging from
T1 to T4, n = 25), the mean number of headache attacks per
month requiring a pain reliever was of 21.0 ± 23.6 (median 16,
IQR 5–30, p < 0.001, data not shown).
Considering pain intensity, the mean VAS score at T0 in the
30 enrolled patients was of 8.0 ± 2.0 (median 8.5, IQR 8–9)
(Fig. 2B). At T1 (25 observed patients), the mean VAS score
significantly decreased to 5.0 ± 2.4 (median 5.0, IQR 3–7;
p < 0.001). This significant reduction in pain intensity was
confirmed also at T2 (19 patients; mean VAS of 5.4 ± 2.3;
median 5, IQR 4–7; p < 0.001), T3 (15 patients; mean VAS
Fig. 1 Time on treatment with low-dose methadone (LDM) of patients in
1 year of follow-up. Survival curves of patients that dropped out because
of an ADR (continuous line) vs. all the other patients (still on treatment at
month 12/dropouts for inefficacy/dropouts for personal reasons; dotted
line). Importantly, most ADR patients dropped out early after LDM ini-
tiation (median time 14 days, IQ range 7–40). The curves are statistically
different (log-rank Mantel-Cox test; P < 0.0001)
Table 2 Demographic and
clinical data of patients treated
with low-dose methadone




















48, 41–58 47, 28–64.5 49, 47.5–56.7 41.5, 39.5–51.7
Female 8 (72.7%) 3 (60%) 10 (100%) 3 (75%)
Prevalent headache type
Migraine 10 (90.9%) 4 (80%) 10 (100%) 2 (50%)
Tension-type
headache
1 (9.1%) 0 (0%) 0 (0%) 2 (50%)
Cluster headache 0 (0%) 1 (20%) 0 (0%) 0 (0%)
Overused drug/s*
NSAIDs 10 (90.9%) 4 (80%) 10 (100%) 4 (100%)
Opioids 8 (72.7%) 1 (20%) 4 (40%) 4 (100%)
Acetaminophen 5 (45.4%) 1 (20%) 4 (40%) 1 (25%)
Serotonin receptor
agonists
5 (45.4%) 4 (80%) 6 (60%) 2 (50%)
Comorbidities§
Anxiety 9 (81.8%) 2 (40%) 6 (60%) 3 (75%)
Arterial hypertension 3 (27.3%) 2 (40%) 4 (40%) 0 (0%)
Other pain conditions 3 (27.3%) 1 (20%) 2 (20%) 1 (25%)
*Some patients overused more than one drug. § Some patients have more than one concomitant disease in
addition to RCM
ADRs adverse drug reactions, IQR interquartile range, NSAIDs nonsteroidal anti-inflammatory drugs
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of 5.9 ± 2.7; median 7, IQR 4–8; p = 0.001), and T4 (11 pa-
tients; mean VAS of 3.6 ± 2.3; median 3, IQR 2–6; p = 0.004).
At time of the last follow-up available for each patient, the
mean pain intensity was of 4.8 ± 2.3 (median 5, IQR 3–6,
p < 0.001, data not shown).
A similar trend in pain relief was observed also considering
the use of rescue medications (Fig. 2C). At T0, the mean num-
ber of pills used per month was of 163.3 ± 156.3 (median 95,
IQR 34–240). At T1, the use of rescuemedications significant-
ly decreased to a mean of 21.3 ± 29.6 pills per month (median
5, IQR 3–30, p < 0.001). Similarly, at T2, T3, and T4, the
monthly intake of rescue medications was reduced to a mean
of number of 36.4 ± 45.6 pills (median 15, IQR 5–60,
p < 0.001), 30.3 ± 55.5 pills (median 8, IQR 4–20,
p < 0.001), and 21.8 ± 34.3 pills (median 10, IQR 3–16, p =
0.003), respectively. At time of the last follow-up, the mean
number of pills used per month was of 22.2 ± 29.2 (median
15, IQR 3–28, p < 0.001, data not shown).
Ten patients reported clinically relevant ADRs (from low to
moderate grade), requiring LDM discontinuation.
Specifically, five patients had nausea, three vomiting, and
two had constipation. Nine patients who experienced an
ADR dropped out early after LDM initiation (after a median
time of 14 days, IQ 7–40), while one patient dropped out at
month 11. All patients fully recovered after tapered interrup-
tion of LDM. No other ADRs were observed in our sample.
No case of misuse or diversion was observed (data not
shown).
Discussion
This is the first study evaluating the effectiveness and safety of
LDM over a 12-month follow-up period, in patients affected
by RCM with continuous headache and MOH in a real-world
setting. As mentioned above, refractoriness may be diagnosed
when a patient experiences ineffectiveness of at least 2 of 4
prophylactic treatments of different pharmacological classes
[4]. Our results show that in patients affected by RCM, when
tolerated, LDM is an effective option for the prevention of
headache exacerbation, as well as for the reduction of pain
intensity and consumption of rescue medications.
However, a significant portion of patients, despite an initial
benefit from LDM, discontinued the treatment because of
ADRs, although they were expected and non-serious. Even
if the portion of patients developing nausea and vomiting
was quite similar to that observed in other populations [20],
our patients did not develop the expected tolerance to these
ADRs. Accordingly, we cannot exclude that patients with mi-
graine have a disease-related alteration (read as hypersensitiv-
ity) to these disturbances. This phenomenon, being nausea
and vomiting the most frequent causes of LDM withdrawal
in our population, deserves future investigation. Importantly,
the median time to develop ADRs, being rather short
(14 days) after therapy initiation, favored the safety profile
Fig. 2 Effectiveness of low-dose methadone (LDM) on headache attacks,
pain intensity, and the use of rescue medications. LDM decreased the
number of headache exacerbations deserving a pain reliever per month
(A), pain intensity assessed by a visual analogue scale (VAS) (B), and the
number of pills of rescue medications consumed per month (C) at differ-
ent time points of follow-up (T0 (baseline), T1 (30 days following T0), T2
(3 months after T0), T3 (6 months after T0), and T4 (12 months after T0).
Namely, the median number (interquartile range, IQR) of headache exac-
erbations per month was 45 (30–90) at T0, 9 (5–30) at T1, 30 (7–30) at T2,
26 (4–30) at T3, and 16 (5–30) at T4. The median VAS (IQR) was 8.5 (8–
9) at T0, 5 (3–7) at T1, 5 (4–7) at T2, 7 (4–8) at T3, and 3 (2–6) at T4. The
median number of pills of rescue medications (IQR) was 95 (34–240) at
T0, 5 (3–30) at T1, 15 (5–60) at T2, 8 (4–20) at T3, and 10 (3–16) at T4
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as tapering of methadone was quick and easy. Altogether, our
observations suggest that the optimization of the treatment,
including either the association with or a formulation contain-
ing methylnaltrexone, which has been shown to be able to
counteract the constipation [21], would relevantly increase
the persistence on treatment, thus increasing the proportion
of patients that might benefit from LDM. Another interesting
result emerging from our population is that all patients
experiencing ADR were female. An increased sensitivity to
opioid-induced nausea and vomiting in women has been al-
ready reported [22–27], but the underlying mechanism is not
known. In our study, the exclusive involvement of women
may be due to the low number of participants that, however,
per se discourages further subgroup analysis.
The impressive reduction of drug consumption observed in
our study (from a median of 95 pills per month (IQR) (34–
240) to 15 (3–28), p < 0.001) suggests that the initial medica-
tion overuse is mostly driven by the pain intensity. It is worth
noting that this is at odds with the assumption that medication
overuse in patients with migraine is mainly due to a genetic
predisposition to substance abuse [28]. Indeed, when metha-
done is administered to patients with MOH according to a
scheduled plan, it alleviates pain and drug consumption con-
sequently falls. The fact that none of our patients misused
methadone, notwithstanding its well-known abuse potential,
further corroborates the hypothesis that RCM patients with
MOH are not genetically predisposed drug abusers per se
[28], but just deserve an efficacious pain treatment to defeat
the vicious cycle that sustains medication overuse. However,
as no conclusive evidence exists, it would be of paramount
importance to dissect the mechanisms that drive the medica-
tion overuse in patients withmigraine as this could significant-
ly change the therapeutic approach to these patients.
It has been already reported that prescribing methadone for
headache patients is neither glamorous nor lucrative and that it
is a tedious process because of extensive patient education,
controlled substance agreement, and meticulous record keeping
[29]. However, the absence of suitable pharmacological alter-
natives for RCM associated with MOH is associated with an
increased risk of ADRs due to overusedmedications and severe
disability of patients who still seek medical attention after a
number of therapeutic failures [29]. In this context, practitioners
should consider LDM as a potential effective alternative for
these patients. Currently, there are no restrictions for methadone
prescriptions in Italy, since by the release of Law 38/2010 that
specifically deals with the treatment of pain, it can be prescribed
with the same modalities used for any other prescription drugs.
Nonetheless, methadone prescription should still be reserved to
specialists experienced in patients’ education and methadone
handling. The opioid epidemics emerging in the United
States, following to a well-meaning movement emerged in the
United States 20 years ago to promote an adequate treatment of
chronic pain with opioids and causing the death of almost half a
million Americans from drug overdoses, suggests that more
than caution is needed [30]. Despite the low rate of use of
opioids in most European countries [31], the strict adherence
to available guidelines that reserve opioids for headache pa-
tients only in selected cases [32] is both essential and manda-
tory to pursue an optimal management of LDM prophylaxis
and to minimize the occurrence of overuse and ADRs.
Our results have several limitations. Unquestionably, the
major limitation is the small sample size that is however due
to the investigated condition. Considering the low frequency
of the disease and the restrictedness of criteria that candidate a
patient to the treatment, we had to deal with study premises
resembling those of rare diseases, indeed. Although we
planned a self-controlled study to maximize the internal valid-
ity of the study [33, 34], only initial evidence may emerge
from observations in such a small population.
Another relevant drawback is the high rate of early treat-
ment discontinuation, which significantly compromised the
power of the study. It is worth noting that the study has a
pragmatic approach and that the high portion of patients
who discontinued the treatment represents the first valuable
result of the study, indeed. On the one side, it suggests that
only some weeks are needed to understand if patients will
tolerate LDM. On the other side, as discontinuation was
mainly due to gastrointestinal liability, we may hypothesize
that innovative formulations of methadone will significant-
ly decrease the number of patients who discontinue the
treatment. Nevertheless, it is reasonable to consider that
eligible enrolled patients were exclusively those non-
responders to standard treatments, thus suggesting that
LDM can represent a valid prophylactic approach in those
refractory patients.
Conclusions
LDMmay be an effective prophylactic alternative for patients
affected by RCM with continuous headache associated with
MOH refractory to standard treatments. In eligible patients,
after a short initial trial to test tolerability, LDMmay represent
a simple and inexpensive way to bring relief and reduce head-
ache medication overuse, although the frequency of early
ADRs poses major safety concerns. Further research, includ-
ing assessment of methadone plasma levels and pharmacoge-
netic profiling, are needed to understand factors that may in-
fluence the clinical response to LDM in RCM patients. In
addition, randomized controlled trials are needed to confirm
the efficacy and safety of LDM prophylaxis.
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